These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2837319)

  • 1. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.
    Calabro-Jones PM; Aguilera JA; Ward JF; Smoluk GD; Fahey RC
    Cancer Res; 1988 Jul; 48(13):3634-40. PubMed ID: 2837319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
    Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection.
    Smoluk GD; Fahey RC; Calabro-Jones PM; Aguilera JA; Ward JF
    Cancer Res; 1988 Jul; 48(13):3641-7. PubMed ID: 2837320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human pharmacokinetics of WR-2721.
    Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
    Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
    Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase.
    Brown DQ; Shaw LM; Pittock JW; Mann DJ; Hardiman J; Pogach R; Gold J
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1491-3. PubMed ID: 3019966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of the phosphorothioate radioprotectors WR-2721 and WR-3689.
    Livesey JC; Rasey JS; Vertrees S; Freeman LM; Magee S; Nelson NJ; Chin L; Grunbaum Z; Krohn KA
    Pharmacol Ther; 1988; 39(1-3):215-7. PubMed ID: 2849127
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
    Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
    Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721.
    Tabachnik NF; Blackburn P; Peterson CM; Cerami A
    J Pharmacol Exp Ther; 1982 Feb; 220(2):243-6. PubMed ID: 6276531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of amifostine.
    Shaw LM; Bonner H; Lieberman R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor.
    Rasey JS; Krohn KA; Magee S; Nelson N; Chin L
    Radiat Res; 1986 Nov; 108(2):167-75. PubMed ID: 3024202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equilibrium dialysis studies of the binding of radioprotector compounds to DNA.
    Smoluk GD; Fahey RC; Ward JF
    Radiat Res; 1986 Aug; 107(2):194-204. PubMed ID: 3018831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
    Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
    Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278.
    Mitchell JL; Judd GG; Diveley RR; Choe CY; Leyser A
    Carcinogenesis; 1995 Dec; 16(12):3063-8. PubMed ID: 8603486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WR-2721, its derivatives and their radioprotective effects on mammalian cells in culture.
    Mori T; Watanabe M; Horikawa M; Nikaido P; Kimura H; Aoyama T; Sugahara T
    Int J Radiat Biol Relat Stud Phys Chem Med; 1983 Jul; 44(1):41-53. PubMed ID: 6305861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.
    Quiñones HI; List AF; Gerner EW
    Clin Cancer Res; 2002 May; 8(5):1295-300. PubMed ID: 12006551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    Shaw LM; Bonner HS; Brown DQ
    Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei.
    Newton GL; Aguilera JA; Ward JF; Fahey RC
    Radiat Res; 1996 Sep; 146(3):298-305. PubMed ID: 8752308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dephosphorylation of WR-2721 with mouse tissue homogenates.
    Mori T; Nikaido O; Sugahara T
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1529-31. PubMed ID: 6090356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.